Summary of Key Points
Domestic insulin products have successfully entered the US market for the first time (Dongguangyang Pharmaceutical’s glargine insulin, and Jianyou in collaboration with Tonghua Dongbao’s aspart insulin), all manufactured at the production facility in Yidu, Hubei, which participated in the national procurement program. This initiative has compelled companies to reduce costs, improve efficiency, and enhance product quality. As a result, not only has the domestic substitution of imported insulins accelerated (with market share rising from less than 30% to 45%), but these products have also obtained stringent international certifications such as those from the FDA, paving the way for entry into high-end markets in Europe and America. Additionally, companies are taking advantage of this opportunity to expand their presence in grassroots healthcare settings. With multinational pharmaceutical companies gradually withdrawing from certain insulin businesses, domestic insulins are facing dual growth opportunities both domestically and internationally.
Detailed Analysis
1. Domestic Insulins Finally Break into the US Market, Shattering Foreign Monopolies
The US is one of the largest insulin markets in the world, long dominated by giants like Novo Nordisk, Eli Lilly, and Sanofi. This year, two domestic companies made significant breakthroughs:
- Dongguangyang Pharmaceutical’s glargine insulin was commercially shipped to the US for the first time (1.152 million units), becoming the first domestic insulin product to enter the market.
- Jianyou Co., Ltd., in partnership with Tonghua Dongbao, has received FDA approval for its aspart insulin, which is set to be launched soon.
The key to entering the US market is passing the rigorous FDA inspection process (Dongguangyang succeeded on the first attempt, while some Indian companies took three attempts). This demonstrates that the production quality of domestic insulins meets global standards, filling a gap in China’s pharmaceutical exports and giving Chinese companies a louder voice on the international stage.
2. Procurement Programs Are Not a Threat to Quality; They Are Accelerators for International Expansion
There are concerns that procurement programs may lead to reduced product quality, but the opposite is true:
- Quality Improvement: Procurement requirements ensure stable supply and consistent quality; otherwise, companies risk losing their bids. Companies have had to invest in process improvements (e.g., Ganli Pharmaceutical increased production capacity through process optimization) and localize packaging materials (reducing costs and breaking foreign monopolies), bringing their production systems up to international standards.
- Shared Production Lines: Dongguangyang’s procurement and export lines use the same standards, from raw materials to testing. Tang Xinfafa (President of Dongguangyang) stated, “There is no difference in quality between exported and procured drugs; price reductions are achieved through scaled production, not by lowering quality.”
In essence, procurement programs serve as a trial run for international certifications, preparing companies to meet the stringent requirements of European and American markets.
3. Accelerated Domestic Substitution: From 50 Years to Nearly Half of the Market Share
Before the procurement program, imported insulins dominated the domestic market (70%). It was predicted that it would take 50 years for domestic insulins to gain a significant share. However, just two years after the program’s implementation:
- The market share of domestic insulins in hospitals has increased from about 31% to 45%, while that of imported insulins has dropped to 55%.
- This is due to the significant price reductions (e.g., Dongguangyang’s glargine insulin was bid at 78 yuan per unit), making domestic products more affordable for hospitals and patients. Procurement programs have not only made cheaper drugs available but also accelerated the market penetration of domestic insulins.
4. Domestic Market Expansion: Grassroots Healthcare Represents a New Frontier
Insulin is an essential daily need for diabetes patients, and while large hospitals are crowded, grassroots healthcare facilities offer more convenient access. Procurement programs have opened up these markets for domestic companies:
- Policy Support: Winning companies receive quotas for distribution in grassroots medical institutions.
- Company Actions: Ganli Pharmaceutical (which won bids for six insulin categories in the first procurement) has already reached many county-level hospitals, and Dongguangyang is reorganizing its sales network for grassroots markets this year.
- Essential Medicines Catalogue: The 2026 edition of the essential medicines catalogue includes aspart and degludec insulins, which must be available in grassroots hospitals, further driving demand. The potential of grassroots markets is enormous and will become a crucial driver for the growth of domestic insulins.
5. Global Supply Chain Restructuring Creates Opportunities for Domestic Insulins
Multinational pharmaceutical companies are reorganizing their businesses: Novo Nordisk plans to withdraw from the global market for insulin analogs by 2026, and Eli Lilly removed some insulin products from the European market in March this year. This creates opportunities for domestic insulins:
- Domestic insulins have already passed international certifications, ensuring quality.
- They have a cost advantage (e.g., lower costs due to localized packaging materials), making them more competitive compared to imported products.
- Emerging markets (such as Brazil and Indonesia) are gradually accepting domestic insulins, broadening export prospects.
In summary, domestic insulins are entering a golden period of growth, with both accelerated domestic substitution and breakthroughs in overseas markets. The future looks promising for these products.